379 citations
,
May 2016 in “Cochrane library” This review concluded that corticosteroids improve muscle strength and function in boys with Duchenne muscular dystrophy over short-term periods, but evidence on prolonging walking ability remains insufficient, and side effects are common.
407 citations
,
January 2008 in “Cochrane Database of Systematic Reviews” This review found that glucocorticoid corticosteroids can improve muscle strength and function in boys with Duchenne muscular dystrophy in the short term, but they are associated with significant short-term adverse effects.
June 2025 in “International Journal of Molecular Sciences” This review compiles current research on the role of long non-coding RNAs in regulating muscle growth and regeneration processes, particularly their influence on Duchenne muscular dystrophy, and reports no new clinical results.
January 2024 in “Wiadomości Lekarskie” This pilot clinical study introduces DEC cells as a novel therapy for Duchenne muscular dystrophy, confirming safety and efficacy in seven patients up to 24 months post-treatment.
July 2026 in “Pharmaceuticals” This review examined mechanisms regulating muscle repair, highlighting disruptions in aging and chronic diseases like Duchenne muscular dystrophy and diabetes. It noted that chronic inflammation and metabolic dysfunction hinder effective regeneration and discussed emerging therapies, suggesting multi-target approaches could be promising despite limited clinical evidence.